Sugi Predict

Sugi Predict / Compounds / SCHEMBL2816698

SCHEMBL2816698

SCHEMBL2816698

CN1C(=O)C(=O)c2cccc(F)c21

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ POLB P06746 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ CASP3 P42574 3/20 0.52
▸ CES1 P23141 2/20 0.50
▸ TTR P02766 1/20 0.50
▸ CHRM5 P08912 3/20 0.49
▸ CHRM1 P11229 2/20 0.45
▸ ALDH3A1 P30838 4/20 0.42
▸ BRD4 O60885 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PARK7 Q99497 1/20 0.38
▸ TRPA1 O75762 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29785238 1.00 ALDH1A1 (0.65) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL5502497 0.85 MEN1 (0.49) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL5001267 0.80 CHRM5 (0.60) ALDH1A1MEN1POLBKMT2ACHRM5
SCHEMBL12536125 0.78 ALDH1A1 (1.00) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL28596272 0.78 MEN1 (0.40) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL4597172 0.77 ALDH1A1 (0.60) ALDH1A1CES1CHRM5CHRM1ALDH3A1
SCHEMBL3778381 0.77 ALDH1A1 (0.65) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL3772043 0.77 ALDH1A1 (0.65) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL11200942 0.77 ALDH1A1 (0.65) ALDH1A1MEN1POLBKMT2ACASP3
SCHEMBL31003694 0.77 ALDH1A1 (0.50) ALDH1A1MEN1POLBKMT2ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed
EP-1963264-A2 NEW 3 -, 7-SUBSTITUTED INDIRUBINS AND THEIR APPLICATIONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-09-03 — — EP disclosed
EP-1869030-A1 7-FLUORO-1,3-DIHYDRO-INDOL-2-ONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS Pharmacia & Upjohn Company LLC (US) 2007-12-26 — — EP disclosed
WO-2007099402-A2 NEW 3’-, 7-SUBSTITUTED INDIRUBINS AND THEIR APPLICATIONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-09-07 — — WO disclosed
EP-1781643-A1 OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS Pharmacia & Upjohn Company LLC (US) 2007-05-09 — — EP disclosed
EP-1781642-A1 OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS Pharmacia & Upjohn Company LLC (US) 2007-05-09 — — EP disclosed
WO-2006106427-A1 7-FLUORO-1,3-DIHYDRO-INDOL-2-ONE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-12 — — WO disclosed
US-20060229349-A1 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents JOSYULA VARA PRASAD V N 2006-10-12 — — US disclosed
WO-2006016220-A1 OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-16 — — WO disclosed
WO-2006016221-A1 OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-16 — — WO disclosed
US-20060030609-A1 Oxazolidinones containing oxindoles as antibacterial agents LUEHR GARY W 2006-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229349-A1 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents OXA1L, MRPL21, FOXM1 ALDH1A1 420/4885MEN1 1624/4885POLB 2385/4885
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR ALDH1A1 2642/4885MEN1 457/4885POLB 3210/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 ALDH1A1 2427/4885MEN1 515/4885POLB 3071/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR ALDH1A1 2642/4885MEN1 457/4885POLB 3210/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALDH1A1 2427/4885MEN1 515/4885POLB 3071/4885
US-20060030609-A1 Oxazolidinones containing oxindoles as antibacterial agents OXA1L, OXSR1, OXER1 ALDH1A1 894/4885MEN1 1292/4885POLB 3273/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALDH1A1 2427/4885MEN1 515/4885POLB 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.